anti-CSP monoclonal antibody (GSK/Ehime University/Eisai/PATH)

N/A

Report date: 2025/03/14 16:55:26

Base Information

Drug Nameanti-CSP monoclonal antibody (GSK/Ehime University/Eisai/PATH)
Drug Alias Nameanti-CSP monoclonal antibody (Glaxosmithkline/Ehime University/Eisai/PATH)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionApical membrane antigen 1 inhibitors
TargetsApical membrane antigen 1
Therapy Area/IndicationsMalaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPath
China Registration ClassN/A

Develop Information

Active CompaniesEhime UniversityGlaxosmithkline PlcPath +[4] 
Inactive CompaniesN/A
Active IndicationsMalaria
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A